Brief: Ensysce Biosciences PF614 Phase 3 Protocol Being Finalized For Submission To FDA
14/08/2024 22:23
Aug 14 (Reuters) - Ensysce Biosciences Inc ENSC.O :
* ENSYSCE BIOSCIENCES: PF614 PHASE 3 PROTOCOL BEING
FINALIZED FOR
SUBMISSION TO FDA
Source text for Eikon: ID:n0001493152-24-032272
Further company coverage: ENSC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ensysce Biosciences
See all newsEnsysce Biosciences Q2 net loss widens on higher R&D costs
Ensysce Biosciences Inc expected to post a loss of 50 cents a share - Earnings Preview
NASDAQ RESUMED AT 09:47 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:42 AM
Brief: Ensysce Biosciences Launches Formal Review Of Strategic Alternatives - SEC Filing